The Trump administration is launching a new effort to bolster domestic clinical trials for new pharmaceutical products after a year of tumult at the federal health agencies that has slowed down new product approvals and frustrated drugmakers.
Health and Human Services Secretary Robert F. Kennedy Jr. said in a press release that the project, called Operation Trial Blazer, is meant to “restore America’s leadership in clinical research, remove unnecessary barriers, and bring more clinical research and investment back to the United States.”
Recommended Stories
“America should be the best place in the world to develop new medicines, yet we have built a system that drives too much clinical research overseas,” Kennedy said.
The move is primarily a joint effort between the National Institutes of Health and the Food and Drug Administration to streamline clinical trial research.
Acting FDA Commissioner Kyle Diamantas told reporters ahead of the announcement that his agency is developing a pilot program for Phase 1 clinical trials and clarifying expectations for trial sponsors that could reduce timelines by 6-12 months.
“This is an ongoing process,” Diamantas said. “FDA will continue to collaborate with academia, government, and the private sector to ensure a regulatory framework is responsive to the realities of modern science.”
Leadership at the FDA has been in flux since President Donald Trump took office in January 2025, creating what drugmakers have characterized as an unstable regulatory environment that disincentivizes expensive research projects.
Diamantas took the reins at the FDA after former Commissioner Marty Makary abruptly left his post, reportedly resigning following a controversy with the president regarding approvals for new flavored vaping products.
The Center for Biologics Evaluation and Research at the FDA, a key department overseeing vaccines and new gene therapy drugs, has also undergone a recent change in leadership with the departure of the controversial Dr. Vinay Prasad, who left the agency at the end of May.
Prasad’s tenure was marred by multiple messy disputes between the agency and drug developers, who accused the CBER director of flip-flopping on guidance for rare disease therapies.
Prasad’s last high-profile controversy was to nix Moderna’s mRNA flu vaccine after it had followed the guidelines established for its clinical trial process set by former Biden administration officials. As of Monday, the agency is poised to review Moderna’s new flu vaccine after an FDA advisory committee unanimously green-lit the project.
Karim Mikhail, the newest acting CBER Director, is the fourth acting director and the sixth leader of the center since January 2025. The other side of drug approvals, the Center for Drug Evaluation and Research, has also experienced six different leaders since the start of the Trump administration.
Complementing the FDA’s efforts to stabilize U.S. biotechnology investment, various branches of the NIH, including the National Center for Advancing Translational Science and the National Cancer Institute, are working to power early-stage clinical research with new advances in technology, including artificial intelligence and cell-based models.
NIH Director Jay Bhattacharya told reporters that his agency’s main goal is to develop so-called “reusable networks” that can expedite clinical trials.
“NIH shall be leveraging our clinical trial network to pilot new trial design, activation processes, participant recruitment and retention, contacting regulatory readiness, and oversight,” Bhattacharya said. “The goal is a reusable network, so that when we build trial infrastructure, it’s possible to use it not just for one trial but for many.”
Operation Trial Blazer comes as China has become a leading challenger to the U.S. in terms of biotechnology development, including clinical trials.
Between 2019 and 2024, China’s share in the global clinical trial market surged by 66% while North America saw a modest increase of only 5%.
That’s in part because China’s version of the FDA, the National Medical Products Administration, quadrupled its workforce between 2015 and 2019, clearing the sizable backlog of new medication approvals.
The FDA requires that late-stage clinical trials for new drugs conducted in China be replicated either in the U.S., Europe, or Australia to ensure the product is safe for an ethnically heterogeneous population.
But pharmaceutical companies frequently use China’s biomedical research infrastructure for early-stage research, including synthesizing chemical compounds that eventually become new pharmaceuticals.
TIMELINE OF FAUCI’S INVOLVEMENT IN THE ORIGIN OF COVID-19 DEBATE
Senior HHS officials did not directly reference competition from China in their announcement, but the press release on the new endeavor stressed that the increase in early-stage clinical trials overseas is “threatening America’s position as the global leader in biomedical innovation.”
“America led the world in medical innovation before,” Kennedy said in his press statement. “We will lead again.”
